Logo image of ADN

ADVENT TECHNOLOGIES HOLDINGS (ADN) Stock Fundamental Analysis

NASDAQ:ADN - Nasdaq - US00788A2042 - Common Stock - Currency: USD

2.42  -0.21 (-7.98%)

Fundamental Rating

2

Overall ADN gets a fundamental rating of 2 out of 10. We evaluated ADN against 94 industry peers in the Electrical Equipment industry. ADN has a bad profitability rating. Also its financial health evaluation is rather negative. ADN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ADN had negative earnings in the past year.
ADN had a negative operating cash flow in the past year.
In the past 5 years ADN always reported negative net income.
In the past 5 years ADN always reported negative operating cash flow.
ADN Yearly Net Income VS EBIT VS OCF VS FCFADN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -885.29%, ADN is not doing good in the industry: 96.81% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -885.29%
ROE N/A
ROIC N/A
ROA(3y)-100.37%
ROA(5y)-96.93%
ROE(3y)-220.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADN Yearly ROA, ROE, ROICADN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -200 -400

1.3 Margins

ADN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADN Yearly Profit, Operating, Gross MarginsADN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ADN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADN has more shares outstanding
Compared to 5 years ago, ADN has more shares outstanding
ADN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADN Yearly Shares OutstandingADN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
ADN Yearly Total Debt VS Total AssetsADN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

ADN has an Altman-Z score of -63.92. This is a bad value and indicates that ADN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -63.92, ADN is not doing good in the industry: 95.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -63.92
ROIC/WACCN/A
WACC10.15%
ADN Yearly LT Debt VS Equity VS FCFADN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

ADN has a Current Ratio of 0.06. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
ADN has a Current ratio of 0.06. This is amonst the worse of the industry: ADN underperforms 93.62% of its industry peers.
ADN has a Quick Ratio of 0.06. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ADN (0.05) is worse than 93.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.05
ADN Yearly Current Assets VS Current LiabilitesADN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

ADN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.87%, which is quite impressive.
Looking at the last year, ADN shows a quite strong growth in Revenue. The Revenue has grown by 10.92% in the last year.
The Revenue has been growing by 67.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)48.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.19%
Revenue 1Y (TTM)10.92%
Revenue growth 3Y76.57%
Revenue growth 5Y67.03%
Sales Q2Q%-89.84%

3.2 Future

Based on estimates for the next years, ADN will show a very strong growth in Earnings Per Share. The EPS will grow by 44.75% on average per year.
Based on estimates for the next years, ADN will show a very strong growth in Revenue. The Revenue will grow by 633.14% on average per year.
EPS Next Y98.1%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2705.94%
Revenue Next 2Y633.14%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADN Yearly Revenue VS EstimatesADN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADN Yearly EPS VS EstimatesADN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

ADN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 23.96, which indicates a rather expensive current valuation of ADN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADN indicates a somewhat cheap valuation: ADN is cheaper than 72.34% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.13. ADN is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 23.96
ADN Price Earnings VS Forward Price EarningsADN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADN Per share dataADN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

ADN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADN's earnings are expected to grow with 44.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVENT TECHNOLOGIES HOLDINGS

NASDAQ:ADN (6/13/2025, 8:00:00 PM)

2.42

-0.21 (-7.98%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)06-06 2025-06-06/amc
Earnings (Next)10-13 2025-10-13
Inst Owners7.03%
Inst Owner Change-87.82%
Ins Owners11.63%
Ins Owner Change0%
Market Cap6.39M
Analysts45
Price TargetN/A
Short Float %1.19%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 23.96
P/S 1.08
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-26.95
EYN/A
EPS(NY)0.1
Fwd EY4.17%
FCF(TTM)-4.03
FCFYN/A
OCF(TTM)-3.96
OCFYN/A
SpS2.23
BVpS-6.85
TBVpS-6.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -885.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.37%
ROA(5y)-96.93%
ROE(3y)-220.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.74%
Cap/Sales 2.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.05
Altman-Z -63.92
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)197.26%
Cap/Depr(5y)268.79%
Cap/Sales(3y)91.22%
Cap/Sales(5y)58.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.19%
EPS Next Y98.1%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.92%
Revenue growth 3Y76.57%
Revenue growth 5Y67.03%
Sales Q2Q%-89.84%
Revenue Next Year2705.94%
Revenue Next 2Y633.14%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.84%
OCF growth 3YN/A
OCF growth 5YN/A